리서치사:Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
발행일:2024년 08월
페이지 정보:영문 250 Pages
라이선스 & 가격 (부가세 별도)
한글목차
세계의 통증 관리 의약품 시장은 2030년까지 929억 달러에 도달할 전망
2023년에 763억 달러로 평가된 세계의 통증 관리 의약품 시장은 분석 기간 2023년부터 2030년까지 CAGR 2.8%로 성장할 전망이며, 2030년에는 929억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 오피오이드 의약품은 CAGR 2.5%로 성장을 지속하고, 분석 기간 종료 시 249억 달러에 달할 것으로 예측됩니다. 비스테로이드성 항염증제(NSAIDS) 분야의 성장률은 분석 기간 동안 CAGR 2.5%로 추정됩니다.
미국 시장은 208억 달러로 추정, 중국은 CAGR 5.5%로 성장 예측
미국의 통증 관리 의약품 시장은 2023년 208억 달러로 평가되었습니다. 세계 2위 경제대국인 중국은 2030년까지 186억 달러 규모에 이를 것으로 예측되며, 분석 기간 2023년부터 2030년까지 CAGR은 5.5%로 전망됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 0.9%와 2.1%로 예측되고 있습니다. 유럽에서는 독일이 CAGR 1.4%로 성장할 것으로 예측됩니다.
세계의 통증 관리 의약품물 시장-주요 동향 및 촉진요인 요약
통증 관리 의약품은 급성 및 만성 통증에서 관절염, 암, 신경 장애와 같은 수술 및 병리로 인한 통증에 이르기까지 다양한 유형의 통증을 완화하도록 설계된 광범위한 의약품을 포함합니다. 이러한 약물에는 비스테로이드성 항염증제(NSAIDs), 오피오이드, 항경련제, 항우울제, 국소 진통제 등이 포함됩니다. 통증 관리 의약품의 각 카테고리는 다른 통증 경로를 표적으로 하는 명확한 메커니즘으로 작용하여 환자에게 맞는 완화를 제공합니다. 이 약 시장은 광대하고 지속적으로 진화하고 있습니다. 효능의 향상, 부작용의 경감, 비중독성 진통제의 개발에 의한 오피오이드 위기에 대한 대처를 목표로 한 연구개발이 진행되고 있습니다.
통증 관리의 혁신은 생명 공학과 약리학의 진보에 힘쓰고 있습니다. 예를 들어, 생물학적 제형과 바이오시밀러의 출현은 큰 도약을 의미하며, 더 적은 부작용으로 표적을 좁힌 진통을 가능하게 합니다. 또한, 서방형 제형 및 경피 투여 시스템의 개발은 통증 관리 치료의 편의성과 어드히어런스를 향상시킵니다. 유전자 검사 및 바이오마커의 확인은 개별 환자의 필요에 맞게 보다 정확하고 효과적인 치료 계획을 가능하게 하며, 개인화된 의료도 이 분야에서 전진하고 있습니다. 이러한 기술적 진보 외에도 통증 완화를 최적화하고 환자 결과를 향상시키기 위해 서로 다른 유형의 약물과 비 약리학 적 개입을 결합한 다중 모드 통증 관리 전략의 사용을 지원하는 임상 증거 축적이 진행 중입니다.
통증 관리 의약품 시장의 성장은 여러 요인에 의해 견인되고 있습니다. 관절염, 요통, 신경장애성 통증 등의 만성 통증이 증가하고 효과적인 통증 관리 솔루션에 대한 수요가 증가하고 있는 것이 큰 요인입니다. 경피 패치 및 임베디드 장치와 같은 약물 전달 기술의 진보는 통증 완화의 새로운 투여 방법을 제공함으로써 대응 가능한 시장을 확대하고 있습니다. 노인들은 만성 통증 상태로 고통받을 가능성이 높기 때문에 세계 인구의 고령화도 시장 성장에 기여합니다. 게다가 고통과 관련된 질병에 대한 인식과 진단이 높아지고 있다는 점도 시장 수요를 뒷받침하고 있습니다. 새로운 통증 관리 의약품물 개발에 대한 규제 당국의 지원과 더 안전한 대체품의 보급으로 오피오이드 위기와의 싸움에 대한 이니셔티브는 시장 확대를 더욱 자극하고 있습니다. 게다가, 통증 관리 치료를 개인의 유전자 프로파일에 맞추어 조정하는 맞춤형 의료의 경향의 높아짐이, 채용을 뒷받침해, 치료 효과를 높이고 있습니다. 이러한 요인들이 함께, 통증 관리 의약품 시장은 역동적이고 빠르게 확대되고 있습니다.
조사 대상 기업 예(전 86건)
AdvaCare Pharma
Daiichi Sankyo Co., Ld.
Eisai Co., Ltd.
Eli Lilly & Company
Endo Pharmaceuticals, Inc.
Fresenius Kabi USA
IBSA Institute Biochimique SA
Mallinckrodt Pharmaceuticals
Merck & Co. Inc.
Neuracle Lifesciences Private Limited
Novartis AG
Pfizer, Inc.
Purdue Pharma LP
Teva Pharmaceutical Industries Ltd.
Viatris, Inc.;
목차
제1장 조사 방법
제2장 주요 요약
시장 개요
주요 기업
시장 동향 및 촉진요인
세계 시장 전망
제3장 시장 분석
미국
캐나다
일본
중국
유럽
프랑스
독일
이탈리아
영국
스페인
러시아
기타 유럽
아시아태평양
호주
인도
한국
기타 아시아태평양
라틴아메리카
아르헨티나
브라질
멕시코
기타 라틴아메리카
중동
이란
이스라엘
사우디아라비아
아랍에미리트(UAE)
기타 중동
아프리카
제4장 경쟁
AJY
영문 목차
영문목차
Global Pain Management Drugs Market to Reach US$92.9 Billion by 2030
The global market for Pain Management Drugs estimated at US$76.3 Billion in the year 2023, is expected to reach US$92.9 Billion by 2030, growing at a CAGR of 2.8% over the analysis period 2023-2030. Opioid Drugs, one of the segments analyzed in the report, is expected to record a 2.5% CAGR and reach US$24.9 Billion by the end of the analysis period. Growth in the NSAIDS segment is estimated at 2.5% CAGR over the analysis period.
The U.S. Market is Estimated at US$20.8 Billion While China is Forecast to Grow at 5.5% CAGR
The Pain Management Drugs market in the U.S. is estimated at US$20.8 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$18.6 Billion by the year 2030 trailing a CAGR of 5.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.9% and 2.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.4% CAGR.
Global Pain Management Drugs Market - Key Trends and Drivers Summarized
Pain management drugs encompass a broad spectrum of medications designed to alleviate various types of pain, ranging from acute and chronic pain to pain resulting from surgeries or medical conditions such as arthritis, cancer, and neuropathy. These drugs include nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, anticonvulsants, antidepressants, and topical analgesics. Each category of pain management drugs operates through distinct mechanisms to target different pain pathways, providing tailored relief to patients. The market for these drugs is vast and continually evolving, driven by ongoing research and development efforts aimed at enhancing efficacy, reducing side effects, and addressing the opioid crisis through the development of non-addictive painkillers.
Innovations in pain management are being fueled by advancements in biotechnology and pharmacology. The emergence of biologics and biosimilars, for instance, represents a significant leap forward, offering targeted pain relief with potentially fewer side effects. Additionally, the development of extended-release formulations and transdermal delivery systems has improved the convenience and adherence to pain management regimens. Personalized medicine is also making headway in this field, with genetic testing and biomarker identification enabling more precise and effective treatment plans tailored to individual patient needs. These technological strides are complemented by a growing body of clinical evidence supporting the use of multimodal pain management strategies, which combine different classes of drugs and non-pharmacological interventions to optimize pain relief and enhance patient outcomes.
The growth in the pain management drugs market is driven by several factors. A significant driver is the rising prevalence of chronic pain conditions such as arthritis, back pain, and neuropathic pain, which increases the demand for effective pain management solutions. Advances in drug delivery technologies, including transdermal patches and implantable devices, have expanded the addressable market by offering new ways to administer pain relief. The aging global population also contributes to market growth, as older adults are more likely to suffer from chronic pain conditions. Additionally, increasing awareness and diagnosis of pain-related conditions have propelled market demand. Regulatory support for the development of new pain management drugs, along with initiatives to combat the opioid crisis by promoting safer alternatives, further stimulates market expansion. Moreover, the growing trend of personalized medicine, which tailors pain management therapies to individual genetic profiles, drives adoption and enhances treatment efficacy. Collectively, these factors are shaping a dynamic and rapidly expanding market for pain management drugs.
Select Competitors (Total 86 Featured) -
AdvaCare Pharma
Daiichi Sankyo Co., Ld.
Eisai Co., Ltd.
Eli Lilly & Company
Endo Pharmaceuticals, Inc.
Fresenius Kabi USA
IBSA Institute Biochimique SA
Mallinckrodt Pharmaceuticals
Merck & Co. Inc.
Neuracle Lifesciences Private Limited
Novartis AG
Pfizer, Inc.
Purdue Pharma L.P.
Teva Pharmaceutical Industries Ltd.
Viatris, Inc.;
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
Global Economic Update
Pain Management Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Prevalence of Chronic Pain Conditions Spurs Demand for Effective Therapies
Aging Population Expands Addressable Market Opportunity for Pain Management Drugs
Advances in Drug Delivery Technologies Propel Growth in Market Adoption
Development of Non-Addictive Painkillers Strengthens Business Case for Safer Alternatives
Personalized Medicine and Genetic Testing Drive Adoption of Tailored Pain Therapies
Emergence of Biologics and Biosimilars Generates New Market Opportunities
Increasing Awareness and Diagnosis of Pain-Related Conditions Accelerates Demand
Integration of Multimodal Pain Management Strategies Sustains Growth in Treatment Approaches
Here's How Extended-Release Formulations Enhance Patient Adherence
Technological Innovations in Transdermal and Implantable Devices Throw the Spotlight On Advanced Pain Relief Methods
Expansion of Healthcare Infrastructure in Emerging Markets Generates Demand for Pain Management Drugs
Rising Trend of Non-Pharmacological Interventions in Pain Management Generates Complementary Market Opportunities
Increasing Investment in Biotechnology Propels Growth in Novel Pain Therapies
Adoption of Telemedicine and Digital Health Technologies Expands Access to Pain Management Solutions
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Pain Management Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Pain Management Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 3: World Historic Review for Pain Management Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 4: World 16-Year Perspective for Pain Management Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Opioid Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 6: World Historic Review for Opioid Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 7: World 16-Year Perspective for Opioid Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for NSAIDS by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 9: World Historic Review for NSAIDS by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 10: World 16-Year Perspective for NSAIDS by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Non-Narcotic Analgesics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 12: World Historic Review for Non-Narcotic Analgesics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 13: World 16-Year Perspective for Non-Narcotic Analgesics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Antimigraine Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 15: World Historic Review for Antimigraine Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 16: World 16-Year Perspective for Antimigraine Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 18: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 19: World 16-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Chronic Pain by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 21: World Historic Review for Chronic Pain by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 22: World 16-Year Perspective for Chronic Pain by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for Acute Pain by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 24: World Historic Review for Acute Pain by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 25: World 16-Year Perspective for Acute Pain by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
Pain Management Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
TABLE 26: USA Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 27: USA Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 28: USA 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
TABLE 29: USA Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 30: USA Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 31: USA 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030
CANADA
TABLE 32: Canada Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 33: Canada Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 34: Canada 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
TABLE 35: Canada Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 36: Canada Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 37: Canada 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030
JAPAN
Pain Management Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 38: Japan Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 39: Japan Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 40: Japan 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
TABLE 41: Japan Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 42: Japan Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 43: Japan 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030
CHINA
Pain Management Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 44: China Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 45: China Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 46: China 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
TABLE 47: China Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 48: China Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 49: China 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030
EUROPE
Pain Management Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
TABLE 50: Europe Recent Past, Current & Future Analysis for Pain Management Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 51: Europe Historic Review for Pain Management Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 52: Europe 16-Year Perspective for Pain Management Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
TABLE 53: Europe Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 54: Europe Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 55: Europe 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
TABLE 56: Europe Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 57: Europe Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 58: Europe 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030
FRANCE
Pain Management Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 59: France Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 60: France Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 61: France 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
TABLE 62: France Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 63: France Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 64: France 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030
GERMANY
Pain Management Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 65: Germany Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 66: Germany Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 67: Germany 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
TABLE 68: Germany Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 69: Germany Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 70: Germany 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030
ITALY
TABLE 71: Italy Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 72: Italy Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 73: Italy 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
TABLE 74: Italy Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 75: Italy Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 76: Italy 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030
UNITED KINGDOM
Pain Management Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 77: UK Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 78: UK Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 79: UK 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
TABLE 80: UK Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 81: UK Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 82: UK 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030
SPAIN
TABLE 83: Spain Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 84: Spain Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 85: Spain 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
TABLE 86: Spain Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 87: Spain Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 88: Spain 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030
RUSSIA
TABLE 89: Russia Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 90: Russia Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 91: Russia 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
TABLE 92: Russia Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 93: Russia Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 94: Russia 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030
REST OF EUROPE
TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 96: Rest of Europe Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 97: Rest of Europe 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 99: Rest of Europe Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 100: Rest of Europe 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030
ASIA-PACIFIC
Pain Management Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Pain Management Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 102: Asia-Pacific Historic Review for Pain Management Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 103: Asia-Pacific 16-Year Perspective for Pain Management Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 105: Asia-Pacific Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 106: Asia-Pacific 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 108: Asia-Pacific Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 109: Asia-Pacific 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030
AUSTRALIA
Pain Management Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
TABLE 110: Australia Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 111: Australia Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 112: Australia 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
TABLE 113: Australia Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 114: Australia Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 115: Australia 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030
INDIA
Pain Management Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
TABLE 116: India Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 117: India Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 118: India 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
TABLE 119: India Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 120: India Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 121: India 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030
SOUTH KOREA
TABLE 122: South Korea Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 123: South Korea Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 124: South Korea 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
TABLE 125: South Korea Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 126: South Korea Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 127: South Korea 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030
REST OF ASIA-PACIFIC
TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 129: Rest of Asia-Pacific Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 132: Rest of Asia-Pacific Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030
LATIN AMERICA
Pain Management Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
TABLE 134: Latin America Recent Past, Current & Future Analysis for Pain Management Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 135: Latin America Historic Review for Pain Management Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 136: Latin America 16-Year Perspective for Pain Management Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
TABLE 137: Latin America Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 138: Latin America Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 139: Latin America 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
TABLE 140: Latin America Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 141: Latin America Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 142: Latin America 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030
ARGENTINA
TABLE 143: Argentina Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 144: Argentina Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 145: Argentina 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
TABLE 146: Argentina Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 147: Argentina Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 148: Argentina 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030
BRAZIL
TABLE 149: Brazil Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 150: Brazil Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 151: Brazil 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
TABLE 152: Brazil Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 153: Brazil Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 154: Brazil 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030
MEXICO
TABLE 155: Mexico Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 156: Mexico Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 157: Mexico 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
TABLE 158: Mexico Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 159: Mexico Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 160: Mexico 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030
REST OF LATIN AMERICA
TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 162: Rest of Latin America Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 163: Rest of Latin America 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 165: Rest of Latin America Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 166: Rest of Latin America 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030
MIDDLE EAST
Pain Management Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
TABLE 167: Middle East Recent Past, Current & Future Analysis for Pain Management Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 168: Middle East Historic Review for Pain Management Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 169: Middle East 16-Year Perspective for Pain Management Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
TABLE 170: Middle East Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 171: Middle East Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 172: Middle East 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
TABLE 173: Middle East Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 174: Middle East Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 175: Middle East 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030
IRAN
TABLE 176: Iran Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 177: Iran Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 178: Iran 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
TABLE 179: Iran Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 180: Iran Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 181: Iran 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030
ISRAEL
TABLE 182: Israel Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 183: Israel Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 184: Israel 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
TABLE 185: Israel Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 186: Israel Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 187: Israel 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030
SAUDI ARABIA
TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 189: Saudi Arabia Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 190: Saudi Arabia 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 192: Saudi Arabia Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 193: Saudi Arabia 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030
UNITED ARAB EMIRATES
TABLE 194: UAE Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 195: UAE Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 196: UAE 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
TABLE 197: UAE Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 198: UAE Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 199: UAE 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030
REST OF MIDDLE EAST
TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 201: Rest of Middle East Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 202: Rest of Middle East 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 204: Rest of Middle East Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 205: Rest of Middle East 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030
AFRICA
Pain Management Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
TABLE 206: Africa Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 207: Africa Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 208: Africa 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
TABLE 209: Africa Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 210: Africa Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 211: Africa 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030